Vir Biotechnology Inc (VIR)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Inventory turnover | — | — | — | 7.66 | — |
| Receivables turnover | — | — | — | — | — |
| Payables turnover | — | — | — | — | — |
| Working capital turnover | 0.08 | 0.06 | 0.79 | 0.89 | 0.11 |
Based on the provided data for Vir Biotechnology Inc, let's analyze the activity ratios:
1. Inventory Turnover:
- December 31, 2021: 7.66
- This ratio indicates that the company turned over its inventory 7.66 times during the year. A higher turnover implies more efficient management of inventory levels.
2. Receivables Turnover:
- Not available for all years.
- The absence of data for receivables turnover makes it difficult to assess how quickly the company is collecting its accounts receivables from customers.
3. Payables Turnover:
- Not available for all years.
- Without information on payables turnover, it is challenging to evaluate how quickly the company is paying its suppliers.
4. Working Capital Turnover:
- December 31, 2021: 0.89
- December 31, 2022: 0.79
- December 31, 2023: 0.06
- December 31, 2024: 0.08
- This ratio indicates how effectively the company is utilizing its working capital to generate revenue. A higher turnover is generally preferred since it suggests the company is generating more revenue per unit of working capital.
In summary, Vir Biotechnology Inc has shown a varying trend in activity ratios. The company's inventory turnover indicates efficient inventory management in 2021. However, the lack of data for receivables and payables turnovers makes it challenging to assess the efficiency of the company's accounts receivables and payables management. The working capital turnover ratios reflect fluctuations over the years, suggesting changes in the company's efficiency in utilizing its working capital to generate revenue. Further analysis and trend evaluation could provide more insights into the company's operational efficiency.
Average number of days
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | — | — | — | 47.62 | — |
| Days of sales outstanding (DSO) | days | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — |
Based on the provided data for Vir Biotechnology Inc, we can analyze the following activity ratios:
1. Days of Inventory on Hand (DOH):
- As of December 31, 2020, the company did not provide the number of days of inventory on hand.
- As of December 31, 2021, Vir Biotechnology had an average of 47.62 days of inventory on hand.
- The data for the years 2022, 2023, and 2024 are not available for analysis.
2. Days of Sales Outstanding (DSO):
- There was no data provided for days of sales outstanding for all the years from 2020 to 2024. This ratio is crucial for assessing the efficiency of the company in collecting receivables from customers.
3. Number of Days of Payables:
- The company did not disclose the number of days of payables for the years 2020 to 2024. This ratio is essential for evaluating the time it takes for the company to pay its suppliers.
Overall, the limited data provided hinders a comprehensive analysis of Vir Biotechnology Inc's activity ratios. These ratios are vital for evaluating the efficiency of the company in managing its inventory, collecting receivables, and paying its obligations. Further information would be necessary to conduct a more detailed assessment of the company's operational performance.
Long-term
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Fixed asset turnover | — | — | 8.40 | 8.36 | 4.26 |
| Total asset turnover | 0.05 | 0.04 | 0.56 | 0.56 | 0.08 |
The long-term activity ratios of Vir Biotechnology Inc show improvements over the years based on the data provided.
Fixed asset turnover, which measures the efficiency of the company in generating sales from fixed assets, shows a significant increase from 4.26 in December 2020 to 8.40 in December 2022. This indicates that the company is utilizing its fixed assets more effectively to generate revenue.
Total asset turnover, which assesses the efficiency of the company in generating sales from all assets, also shows an improvement from 0.08 in December 2020 to 0.56 in both December 2021 and December 2022. However, there is a slight decrease in the ratio to 0.04 and 0.05 in December 2023 and December 2024 respectively.
Overall, the increase in fixed asset turnover and total asset turnover ratios suggests that Vir Biotechnology Inc is becoming more efficient in utilizing its assets to generate revenue. However, the decrease in total asset turnover in the later years might indicate a slowdown in the company's ability to generate sales from its total assets, which warrants further investigation to understand the underlying factors contributing to this trend.